Treace Medical Concepts, Inc. (TMCI)
TMCI Stock Price Chart
Explore Treace Medical Concepts, Inc. interactive price chart. Choose custom timeframes to analyze TMCI price movements and trends.
TMCI Company Profile
Discover essential business fundamentals and corporate details for Treace Medical Concepts, Inc. (TMCI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
23 Apr 2021
Employees
432.00
Website
https://www.treace.comCEO
John T. Treace
Description
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
TMCI Financial Timeline
Browse a chronological timeline of Treace Medical Concepts, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.30, while revenue estimate is $44.02m.
Earnings released on 8 May 2026
EPS came in at -$0.28 surpassing the estimated -$0.31 by +9.68%, while revenue for the quarter reached $47.20m , beating expectations by +2.69%.
Earnings released on 27 Feb 2026
EPS came in at -$0.12 surpassing the estimated -$0.15 by +21.00%, while revenue for the quarter reached $62.52m , beating expectations by +1.08%.
Earnings released on 6 Nov 2025
EPS came in at -$0.26 surpassing the estimated -$0.28 by +7.14%, while revenue for the quarter reached $50.21m , missing expectations by -18.70%.
Earnings released on 7 Aug 2025
EPS came in at -$0.28 surpassing the estimated -$0.29 by +3.45%, while revenue for the quarter reached $47.39m , missing expectations by -4.95%.
Earnings released on 8 May 2025
EPS came in at -$0.25 surpassing the estimated -$0.31 by +19.35%, while revenue for the quarter reached $52.57m , beating expectations by +6.16%.
Earnings released on 27 Feb 2025
EPS came in at -$0.01 surpassing the estimated -$0.04 by +75.00%, while revenue for the quarter reached $68.71m , beating expectations by +2.26%.
Earnings released on 5 Nov 2024
EPS came in at -$0.25 surpassing the estimated -$0.27 by +7.41%, while revenue for the quarter reached $45.09m , missing expectations by -32.65%.
Earnings released on 6 Aug 2024
EPS came in at -$0.34 falling short of the estimated -$0.29 by -17.24%, while revenue for the quarter reached $44.46m , beating expectations by +1.13%.
Earnings released on 7 May 2024
EPS came in at -$0.30 matching the estimated -$0.30, while revenue for the quarter reached $51.11m , beating expectations by +4.17%.
Earnings released on 27 Feb 2024
EPS came in at -$0.10 falling short of the estimated -$0.09 by -11.11%, while revenue for the quarter reached $62.21m , beating expectations by +2.74%.
Earnings released on 9 Nov 2023
EPS came in at -$0.28 falling short of the estimated -$0.26 by -7.69%, while revenue for the quarter reached $40.76m , missing expectations by -30.79%.
Earnings released on 8 Aug 2023
EPS came in at -$0.20 surpassing the estimated -$0.23 by +13.04%, while revenue for the quarter reached $41.95m , beating expectations by +2.70%.
Earnings released on 8 May 2023
EPS came in at -$0.23 matching the estimated -$0.23, while revenue for the quarter reached $42.20m , beating expectations by +7.53%.
Earnings released on 7 Mar 2023
EPS came in at -$0.08 surpassing the estimated -$0.13 by +38.46%, while revenue for the quarter reached $49.77m , beating expectations by +11.22%.
Earnings released on 8 Nov 2022
EPS came in at -$0.22 surpassing the estimated -$0.28 by +21.43%, while revenue for the quarter reached $33.06m , beating expectations by +9.71%.
Earnings released on 9 Aug 2022
EPS came in at -$0.23 falling short of the estimated -$0.21 by -9.52%, while revenue for the quarter reached $29.97m , beating expectations by +4.47%.
Earnings released on 5 May 2022
EPS came in at -$0.16 surpassing the estimated -$0.20 by +20.00%, while revenue for the quarter reached $29.05m , beating expectations by +11.58%.
Earnings released on 3 Mar 2022
EPS came in at -$0.12 falling short of the estimated -$0.01 by -2.30k%, while revenue for the quarter reached $33.44m , beating expectations by +3.35%.
Earnings released on 4 Nov 2021
EPS came in at -$0.12 matching the estimated -$0.12, while revenue for the quarter reached $21.62m , beating expectations by +2.95%.
Earnings released on 5 Aug 2021
EPS came in at -$0.10 surpassing the estimated -$0.12 by +16.67%, while revenue for the quarter reached $20.65m , meeting expectations.
TMCI Stock Performance
Access detailed TMCI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
